Publications by authors named "F Mehnert"
Objectives: Osteoarticular infection (OAI) is a feared complication of Staphylococcus aureus bacteraemia (SAB) and is associated with poor outcomes. We aimed to explore the risk of OAI and death following SAB in patients with and without rheumatoid arthritis (RA) and to identify risk factors for OAI in patients with RA.
Methods: Danish nationwide cohort study of all patients with microbiologically verified first-time SAB between 2006-18.
Objectives: To assess how biological disease-modifying antirheumatic drugs (bDMARDs), glucocorticoids and disease activity affect risk of bacteraemia (SAB) in patients with rheumatoid arthritis (RA).
Methods: In a nationwide cohort of patients with RA from the DANBIO registry, we conducted a nested case-control study including first-time microbiologically verified SAB cases from 2010 to 2018 and incidence density matched controls (1:4 by sex, age). We interlinked Danish registries and identified antirheumatic treatments, RA-specific clinical characteristics, comorbidities and socioeconomic status.
Objective: Successful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).
Methods: Observational cohort study from the DANBIO registry.
Objective: It remains disputed how much the risk of bacteraemia (SAB) is increased in patients with rheumatoid arthritis (RA), and the extent to which orthopaedic implants explain the risk. We assessed SAB incidence rates (IRs) and incidence rate ratios (IRRs), comparing RA patients with a general population cohort (GPC) and individuals with versus without orthopaedic implants.
Method: Danish residents aged ≥ 18 years without prior RA or SAB (=GPC) were followed up for RA and microbiologically verified SAB events (1996-2017).
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Ann Rheum Dis
November 2021
Article Synopsis
- In Denmark, a mandatory shift from the original adalimumab to two biosimilars, GP2017 (Hyrimoz) and SB5 (Imraldi), occurred in 2018, prompting a study to compare their effectiveness for treating rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
- An observational study using the DANBIO registry was conducted, analyzing treatment retention and remission rates through statistical methods, ultimately including 1318 patients who switched to either GP2017 or SB5.
- Results showed that GP2017 had a lower withdrawal risk and higher 6-month remission rates compared to SB5, although conclusions may be influenced by factors like differences in patient groups or variations in the